|
|
Article: Genentech's blockbuster Avastin gains new cancer indication; $2B sales predicted in 2007.
- Article from:
- Pharma Marketletter
- Article date:
- October 23, 2006
CopyrightCOPYRIGHT 2006 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
US biotechnology major Genentech says that the Food and Drug Administration has approved Avastin (bevacizumab) to be used in combination with carboplatin and paclitaxel chemotherapy for the first-line treatment of patients with unresectable, locally-advanced, recurrent or metastatic non- squamous, non-small cell lung cancer, the most common type of lung cancer.
The approval is based on a Phase III study (E4599) that showed Avastin, in combination with chemotherapy, resulted in a 25% improvement in overall survival compared to chemotherapy alone, which makes it the first drug in 10 years to improve on standard first-line treatment for advanced lung cancer and the ...